These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1171 related articles for article (PubMed ID: 19447865)

  • 21. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    Pao W; Miller VA; Politi KA; Riely GJ; Somwar R; Zakowski MF; Kris MG; Varmus H
    PLoS Med; 2005 Mar; 2(3):e73. PubMed ID: 15737014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M; Takahashi T; Yamamoto N; Koh Y
    J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
    Ichihara E; Ohashi K; Takigawa N; Osawa M; Ogino A; Tanimoto M; Kiura K
    Cancer Res; 2009 Jun; 69(12):5091-8. PubMed ID: 19491268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
    Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
    Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
    Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.